Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ImmunityBio (IBRX) Capital Leases (2016 - 2018)

ImmunityBio (IBRX) has disclosed Capital Leases for 3 consecutive years, with $5.9 million as the latest value for Q4 2018.

  • Quarterly Capital Leases rose 241.47% to $5.9 million in Q4 2018 from the year-ago period, while the trailing twelve-month figure was $5.9 million through Dec 2018, up 241.47% year-over-year, with the annual reading at $5.9 million for FY2018, 241.47% up from the prior year.
  • Capital Leases for Q4 2018 was $5.9 million at ImmunityBio, down from $6.1 million in the prior quarter.
  • The five-year high for Capital Leases was $6.3 million in Q2 2018, with the low at $1.7 million in Q1 2018.
  • Average Capital Leases over 3 years is $3.2 million, with a median of $2.0 million recorded in 2016.
  • The sharpest move saw Capital Leases dropped 24.1% in 2017, then soared 241.47% in 2018.
  • Over 3 years, Capital Leases stood at $2.0 million in 2016, then decreased by 14.02% to $1.7 million in 2017, then skyrocketed by 241.47% to $5.9 million in 2018.
  • According to Business Quant data, Capital Leases over the past three periods came in at $5.9 million, $6.1 million, and $6.3 million for Q4 2018, Q3 2018, and Q2 2018 respectively.